MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.217220 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Xinzhao Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Computational…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Nippon Foundation, Kobayashi Foundation for Cancer Research, Takeda Science Foundation.
Abstract (Originalsprache)
Recently approved RET tyrosine kinase inhibitors (TKIs) have shown promising therapeutic effects against RET-rearranged non-small cell lung cancer (NSCLC) or RET-mutated thyroid cancer. However, resistance develops, limiting long-term efficacy. Although many RET-TKI resistance mechanisms, such as secondary mutations in RET or activation of bypass pathways, are known, some primary or acquired resistance mechanisms are unclear. Here, human genome-wide CRISPR/Cas9 screening was performed to identify genes related to drug-tolerant persister cells. Patient-derived cells with RET-fusion were introduced genome-wide sgRNA library and treated with RET-TKI for 9 days, resulting in the discovery of several candidate genes. Knockout of MED12 or MIG6 significantly increased residual drug-tolerant persister cells under RET-TKI treatment. MIG6 loss induced significant EGFR activation even with low concentrations of EGFR ligands and led to resistance to RET-TKIs. EGFR inhibition with afatinib or cetuximab in combination with RET TKIs was effective in addressing drug persistence. By contrast, a KIF5B-RET positive cells established from a RET-rearranged NSCLC patient, showed significant resistance to RET-TKIs and high dependence on EGFR bypass signaling. Consistently, knocking out EGFR or RET led to high sensitivity to RET or EGFR inhibitor respectively. Here, we have provided a comprehensive analysis of adaptive and acquired resistance against RET-rearranged NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, T…
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for C…
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuo…
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Förderung
- Nippon Foundation
- Kobayashi Foundation for Cancer Research
- Takeda Science Foundation
- Japan Agency for Medical Research and Development
- Mitsubishi Foundation
- Japan Society for the Promotion of Science
Zitieren
APA
Wei, X., Uchibori, K., Kondo, N., Utsumi, T., Takemoto, A., Koike, S., Takagi, S., Yanagitani, N., Nishio, M., & Katayama, R. (2024). MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217220
Vancouver
Wei X, Uchibori K, Kondo N, Utsumi T, Takemoto A, Koike S, et al. MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217220
BibTeX
@article{Wei2024,
author = {Wei, Xinzhao and Uchibori, Ken and Kondo, Nobuyuki and Utsumi, Takahiro and Takemoto, Ai and Koike, Sumie and Takagi, Satoshi and Yanagitani, Noriko and Nishio, Makoto and Katayama, Ryohei},
title = {MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.217220}
}
EUVIMED